DSM-Firmenich AG (ETR:ZX6)
Germany · Delayed Price · Currency is EUR | Market Cap | 21.96B +6.8% |
| Revenue (ttm) | 9.06B +10.1% |
| Net Income | -1.41B |
| EPS | -5.56 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 23.24 |
| Dividend | 2.50 (2.73%) |
| Ex-Dividend Date | May 11, 2026 |
| Volume | 2,078 |
| Open | 89.50 |
| Previous Close | 89.86 |
| Day's Range | 89.42 - 90.86 |
| 52-Week Range | 55.42 - 96.60 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 18, 2027 |
About DSM-Firmenich AG
DSM-Firmenich AG provides nutrition, health, and beauty solutions in Switzerland, the Netherlands, rest of Europe, the Middle East and Africa, North America, Latin America, China, and rest of Asia. The company operates through Perfumery & Beauty; Taste, Texture & Health; and Health, Nutrition & Care segments. The Perfumery & Beauty creates scents using natural, synthetic, and biotech ingredients. The Taste, Texture & Health segment provides food and beverages solutions, including flavors, natural extracts, and sugar reduction; and food enzymes,... [Read more]
Financial Performance
Financial StatementsNews
DSM-Firmenich price target raised to EUR 90 from EUR 85 at Morgan Stanley
Morgan Stanley analyst Lisa De Neve raised the firm’s price target on DSM-Firmenich (DSMFF) to EUR 90 from EUR 85 and keeps an Equal Weight rating on the shares. Published…
India investigates fragrance giants over price collusion, document shows
Global fragrance makers Givaudan , Firmenich and International Flavors & Fragrances face a second antitrust investigation by Indian authorities, according to a regulatory document seen by Reuters.
DSM-Firmenich price target raised to EUR 106 from EUR 99 at Citi
Citi raised the firm’s price target on DSM-Firmenich (DSMFF) to EUR 106 from EUR 99 and keeps a Buy rating on the shares.
DSM-Firmenich price target raised to EUR 68 from EUR 60 at JPMorgan
JPMorgan raised the firm’s price target on DSM-Firmenich (DSMFF) to EUR 68 from EUR 60 and keeps an Underweight rating on the shares.
Dsm-firmenich's fragrance-led core profit beat sends shares higher
Dsm-firmenich on Thursday beat market expectations for second-quarter core earnings and said full-year sales growth should reach the upper end of its target range on the back of broad-based volume gr...
DSM-Firmenich AG Earnings Call Transcript: Q2 2026
Strong H1 and Q2 results with robust sales and EBITDA growth, margin improvement, and solid cash generation. Outlook for 2026 is reaffirmed, with cost programs and innovation pipeline supporting future growth, while FX headwinds and restocking effects are closely monitored.
DSM-Firmenich AG Slides: Q2 2026
DSM-Firmenich AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 30, 2026.
DSM-Firmenich AG Earnings release: Q2 2026
DSM-Firmenich AG released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
DSM-Firmenich initiated with an Outperform at Bernstein
Bernstein initiated coverage of DSM-Firmenich (DSMFF) with an Outperform rating and EUR 103 price target The firm says that after 15 years of market outperformance versus chemicals, sector rotation an...
DSM-Firmenich price target raised to EUR 98 from EUR 75 at Deutsche Bank
Deutsche Bank raised the firm’s price target on DSM-Firmenich (DSMFF) to EUR 98 from EUR 75 and keeps a Buy rating on the shares.
DSM-Firmenich price target raised to EUR 99 from EUR 87 at Citi
Citi analyst Sebastian Satz raised the firm’s price target on DSM-Firmenich (DSMFF) to EUR 99 from EUR 87 and keeps a Buy rating on the shares.
DSM-Firmenich price target raised to EUR 73 from EUR 71 at Morgan Stanley
Morgan Stanley analyst Lisa De Neve raised the firm’s price target on DSM-Firmenich (DSMFF) to EUR 73 from EUR 71 and keeps an Equal Weight rating on the shares. Published…
dsm-firmenich receives FDA approval on PARSOL® Shield, a new sun protection ingredient for the U.S.
Press Release dsm-firmenich receives FDA approval on PARSOL® Shield, a new sun protection ingredient for the U.S. Kaiseraugst (Switzerland), Maastricht (Netherlands), June 10, 2026 dsm-firmenich, inno...
DSM-Firmenich downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs downgraded DSM-Firmenich (DSMFF) to Sell from Neutral with a price target of EUR 65, down from EUR 75. The firm made seven rating changes in European chemicals, “positioning…
DSM-Firmenich price target raised to EUR 71 from EUR 69 at Morgan Stanley
Morgan Stanley analyst Lisa De Neve raised the firm’s price target on DSM-Firmenich (DSMFF) to EUR 71 from EUR 69 and keeps an Equal Weight rating on the shares. Published…
DSM-Firmenich price target lowered to EUR 60 from EUR 70 at JPMorgan
JPMorgan lowered the firm’s price target on DSM-Firmenich (DSMFF) to EUR 60 from EUR 70 and keeps an Underweight rating on the shares.
dsm-firmenich shares commence trading on SIX Swiss Exchange, establishing dual listing with Euronext Amsterdam
Press Release dsm-firmenich shares commence trading on SIX Swiss Exchange, establishing dual listing with Euronext Amsterdam Kaiseraugst (Switzerland), Maastricht (Netherlands), May 21, 2026 dsm-firme...
DSM-Firmenich price target raised to EUR 69 from EUR 66 at Morgan Stanley
Morgan Stanley analyst Lisa De Neve raised the firm’s price target on DSM-Firmenich (DSMFF) to EUR 69 from EUR 66 and keeps an Equal Weight rating on the shares. Published…
dsm-firmenich shareholders approve all resolutions at Annual General Meeting 2026
Press Release dsm-firmenich shareholders approve all resolutions at Annual General Meeting 2026 Kaiseraugst (Switzerland), Maastricht (Netherlands), May 7, 2026 dsm-firmenich, innovators in nutrition,...
DSM-Firmenich AG Earnings Call Transcript: Q1 2026
Solid Q1 with 4% volume-driven sales growth and strong Perfumery and Beauty performance. Full-year outlook reaffirmed, margins expected to improve as FX and cost impacts are managed. Dual listing on SIX Swiss Exchange announced to broaden investor base.
DSM-Firmenich AG Earnings release: Q1 2026
DSM-Firmenich AG released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
dsm-firmenich Q1 2026 trading update
Press Release Kaiseraugst (Switzerland), Maastricht (Netherlands), May 6, 2026 dsm-firmenich Q1 2026 trading update Solid start to the year driven by good LFL sales growth Highlights 4% LFL sales grow...
DSM-Firmenich AG Transcript: Investor update
The company has completed its transformation, focusing on specialty ingredients and creation capabilities, with strong progress in synergies, sustainability, and financial performance. 2026–2028 targets include 2%-4% organic sales growth (rising to 4%-6% plus Bovaer), EBITDA margin of 20%-23%, and cash conversion above 14%.
DSM-Firmenich AG Press release: Investor update
DSM-Firmenich AG issued a press release on March 12, 2026, disclosing material business information to investors.
DSM-Firmenich AG Slides: Investor update
DSM-Firmenich AG has posted slides in relation to its latest quarterly earnings report, which was published on March 12, 2026.